Xizang Haisco Pharmaceutical Group

Portfolio · 1

EndoSpan

Stent Graft Systems for Aneurysms and Dissections

1 round $10.0M committed Latest: 2015-10

Investment activity

1 portfolio exit on record.

Q&A

What is Xizang Haisco Pharmaceutical Group's primary investment focus?

Xizang Haisco Pharmaceutical Group primarily focuses its investments within the Health Tech & Life Sciences sector, with all its portfolio companies and exits concentrated in this area.

Can you name a notable exit for Xizang Haisco Pharmaceutical Group?

A notable exit for Xizang Haisco Pharmaceutical Group is EndoSpan, which was acquired by Artivion for $335 million in May 2026.

What is the most recent exit for Xizang Haisco Pharmaceutical Group?

The most recent exit for Xizang Haisco Pharmaceutical Group was the acquisition of EndoSpan by Artivion in May 2026.

What type of investor is Xizang Haisco Pharmaceutical Group?

Xizang Haisco Pharmaceutical Group is a corporate venture capital firm.

When was Xizang Haisco Pharmaceutical Group founded?

Xizang Haisco Pharmaceutical Group was created on May 11, 2019.

What is a key portfolio company for Xizang Haisco Pharmaceutical Group?

A key portfolio company for Xizang Haisco Pharmaceutical Group is EndoSpan, which develops stent graft systems for aneurysms and dissections.